Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients with histologically or cytologically confirmed advanced solid malignancy or Lymphoma~Relapsed or refractory disease after at least 1 prior systemic treatment for the primary malignancy and not a candidate for other curative treatment.~Adequate hematologic status~Adequate coagulation function~Adequate hepatic function~Adequate renal function~Exclusion Criteria:~Known primary tumors of central nervous system disease~Known active brain metastases~Known cardiopulmonary disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Hu5F9-G4) (Type: EXPERIMENTAL): Hu5F9-G4 monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).